3Marnounas EP, Fisher B. Preoperative chemotherapy for operable breast cancer[J].Cancer Treat Res,2000,103: 137-155.
4Sapunar F, Smith IE. Neoadjuvant chemotherapy for breast cancer[J]. Ann Med,2000, 32 (1) : 43-50.
5Bodey B, Bodey BJR,Groger AM,et al. Immunocytochemical detection of the P170 multidrug resistance(MDR) and the P53 tumor suppressor gone protein in humon breast cancer cell. clinical and the therapeutical significance[J].Anticancer Res,1997,17(2B):1311.
6Sun J,He ZG, Cheng G, et al.Multidrug resistance P-glycoprotein crucial significance in drug disposition and interaction[J].Med Sci Monit,2004,10(1):RA5-14.
7Ambudkar SV,Kimchi-Sarfaty C,Sauna ZE, et al.P-glycoprotein from genomics to mechanism [J].Oncogene, 2003,22(47):7468-7485.
8Bodey B, Bodey B J R, Groger A M, et al. Immunocytochemical detection of the P170 multidrug resistance (MDR) and the P53 tumor suppressor gene protein in humen breast cancer cell: clinical and the therapeutical significance [J]. Anticancer Res, 1997, 17 (2B):1311.
9Izquierdo M A, Scheffer G L, Flens M J, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal tissues and tumors [J]. Am J Pathol, 1996, 148 (3): 877.
10Loe D W, Deeley R G, Cole S P. Biology of the multidrug resistanceassociated protein MRP [J]. Euro J Cancer, 1996, 32 (6): 945.
